Brett Leav

2000–2025 年に発表

39
論文数
18,902
被引用数
28
h 指数
37
i10 指数

被引用数

Brett Leav の年別被引用数1969 年: 被引用 1 件1974 年: 被引用 1 件2002 年: 被引用 1 件2003 年: 被引用 6 件2004 年: 被引用 4 件2005 年: 被引用 7 件2006 年: 被引用 9 件2007 年: 被引用 9 件2008 年: 被引用 9 件2009 年: 被引用 8 件2010 年: 被引用 18 件2011 年: 被引用 27 件2012 年: 被引用 34 件2013 年: 被引用 22 件2014 年: 被引用 26 件2015 年: 被引用 22 件2016 年: 被引用 23 件2017 年: 被引用 25 件2018 年: 被引用 12 件2019 年: 被引用 40 件2020 年: 被引用 102 件2021 年: 被引用 2,867 件2022 年: 被引用 2,258 件2023 年: 被引用 815 件2024 年: 被引用 924 件2025 年: 被引用 458 件2026 年: 被引用 10 件1970〜1973 年は被引用が無いため表示していません1975〜2001 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,858 件、この内訳の 26.5%中国: 引用元論文 816 件、この内訳の 7.6%イギリス: 引用元論文 716 件、この内訳の 6.7%イタリア: 引用元論文 481 件、この内訳の 4.5%ドイツ: 引用元論文 464 件、この内訳の 4.3%カナダ: 引用元論文 421 件、この内訳の 3.9%フランス: 引用元論文 274 件、この内訳の 2.6%オーストラリア: 引用元論文 273 件、この内訳の 2.5%スペイン: 引用元論文 251 件、この内訳の 2.3%日本: 引用元論文 250 件、この内訳の 2.3%オランダ: 引用元論文 250 件、この内訳の 2.3%インド: 引用元論文 228 件、この内訳の 2.1%
0%26.5%その他 32.4%

分野

  • Medicine72.2%
  • Biochemistry, Genetics and Molecular Biology14.8%
  • Immunology and Microbiology5%
  • Social Sciences3.1%
  • Mathematics1.5%
  • Materials Science0.5%
  • その他2.9%

トピック

  • SARS-CoV-2 and COVID-19 Research22.1%
  • COVID-19 Clinical Research Studies8.9%
  • Vaccine Coverage and Hesitancy5.5%
  • RNA Interference and Gene Delivery4.8%
  • Animal Virus Infections Studies3.6%
  • Immunotherapy and Immune Responses3.4%
  • その他51.7%

共著者

全論文

検索で開く
  1. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brett Leav, Weiping Deng, Honghong Zhou, Shu Han, Melanie Ivarsson, Jacqueline Miller, Tal Zaks - New England Journal of Medicine 2020 被引用: 10,720

  2. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wendy Buchanan, Catherine J. Luke, Varun K. Phadke, Christina A. Rostad, Julie E. Ledgerwood, Barney S. Graham, John H. Beigel - New England Journal of Medicine 2020 被引用: 1,630

  3. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shu Han, Brett Leav, Deb Manzo, Rolando Pajón, F. Schödel, Joanne E. Tomassini, Honghong Zhou, Jacqueline M. Miller - New England Journal of Medicine 2021 被引用: 658

  4. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials

    著者: , , , , , , , , , , , , , - The Lancet Infectious Diseases 2023 被引用: 141

  5. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mehul S. Suthar, Adrian B. McDermott, Nicole A. Doria‐Rose, Jae Arega, John H. Beigel, Wendy Buchanan, Mohammed Elsafy, Binh Hoang, Rebecca Lampley, Aparna Kolhekar, Hyung Il Koo, Catherine J. Luke, Mamodikoe Makhene, Seema Nayak, Rhonda Pikaart-Tautges, Paul C. Roberts, Janie Russell, Elisa Sindall, Jim Albert, Pratap Kunwar, Mat Makowski, Evan J. Anderson, Amer Bechnak, Mary Bower, Andrés Camacho-González, Matthew H. Collins, Ana Drobeniuc, Venkata Viswanadh Edara, Srilatha Edupuganti, Katharine Floyd, Theda Gibson, Cassie M. Grimsley Ackerley, Brandi Johnson, Satoshi Kamidani, Carol Kao, Colleen F. Kelley, Lilin Lai, Hollie Macenczak, Michele Paine McCullough, Etza Peters, Varun K. Phadke, Paulina A. Rebolledo, Christina A. Rostad, Nadine Rouphael, Erin M. Scherer, Amy C Sherman, Kathy Stephens, Mehul S. Suthar, Mehgan Teherani, Jessica Traenkner, Juton R. Winston, İnci Yıldırım, Lee Barr, Joyce Benoit, Barbara Carste, Joe Choe, Maya Dunstan, Roxanne Erolin, Jana ffitch, Colin Fields, Lisa A. Jackson, Erika Kiniry, Susan Lasicka, Stella E. Lee, M. Nguyen, Stephanie Pimienta, Janice Suyehira, Michael M. Witte, Hamilton Bennett, Nedim Emil Altaras ほか 58 名 - Science 2021 被引用: 602

  6. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

    著者: , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2021 被引用: 449

  7. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

    著者: , , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 371

  8. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 754

  9. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

    著者: , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 144

  10. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John H. Beigel - New England Journal of Medicine 2020 被引用: 829

  11. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

    著者: , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 104

  12. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

    著者: , , , , , , - Vaccine 2021 被引用: 237

  13. Treatment with Monoclonal Antibodies against Clostridium difficile Toxins

    著者: , , , , , , , , , , , - New England Journal of Medicine 2010 被引用: 745

  14. Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Chunla He, Walter L. Straus, Kellie J. MacPhee, Isabel Regadas, Diana Nyabundi, Ruth Chirchir, Omu Anzala, John Kimotho, Caleb K. Kibet, Kelli Greene, Hongmei Gao, Erica L. Beatman, K Benson, Dominick J. Laddy, David M. Brown, Rhianna Bronson, Jalen Baptiste, Suprabhath Gajjala, Zahra Rikhtegaran Tehrani, Alison Benner, Mukundhan Ramaswami, Danny Lu, Nushin Alavi, Sonya Amirzehni, Michael Kubitz, Ryan Tingle, Erik Georgeson, Nicole Phelps, Yumiko Adachi, Alessia Liguori, Claudia Flynn, Katherine McKenney, Xiaoya Zhou, D. Collins Owuor, Sharon Owuor, S Kim, Michael Duff, Ju Yeong Kim, Grace Gibson, Sabyasachi Baboo, Jolene K. Diedrich, Torben Schiffner, Marisa Shields, Mabela Matsoso, Jairo Ivo dos Santos, Kristen Syvertsen, Allison Kennedy, Melissa Schroeter, Johan Vekemans, John R. Yates, James C. Paulson, Ollivier Hyrien, Adrian B. McDermott, Pholo Maenetje, Julien Nyombayire, Etienne Karita, Rosine Ingabire, Vinodh Edward, Vincent Muturi‐Kioi, Janine Maenza, Adrienne E. Shapiro, M. Juliana McElrath, Srilatha Edupuganti, Barbara S. Taylor, David Diemert, Gabriel Ozorowski, Richard A. Koup, David C. Montefiori, Andrew B. Ward, Gunilla B. Karlsson Hedestam ほか 8 名 - Science 2025 被引用: 60

  15. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience

    著者: , , , , - International Journal of Infectious Diseases 2019 被引用: 49

  16. Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees

    著者: , , , , , , , , , , , , , , , , , - PLoS Pathogens 2012 被引用: 166

  17. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial

    著者: , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 36

  18. Retrospective Assessment of the Antigenic Similarity of Egg-Propagated and Cell Culture-Propagated Reference Influenza Viruses as Compared with Circulating Viruses across Influenza Seasons 2002–2003 to 2017–2018

    著者: , , , , , , , - International Journal of Environmental Research and Public Health 2020 被引用: 32

  19. No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial

    著者: , , , , , , , - Human Vaccines & Immunotherapeutics 2024 被引用: 16

  20. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)

    著者: , , , , , , , , , , , - Vaccine 2009 被引用: 244

  21. Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 63

  22. Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study

    著者: , , , , , , , , , , , , , - The Lancet Infectious Diseases 2021 被引用: 48

  23. Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , COVID-19 Prevention Network (CoVPN), Atoya Adams, Eric N. Miller, Bruce G. Rankin, Steven Shinn, Marshall Nash, S Green, Colleen Jacobsen, Jayasree Krishnankutty, Sikhongi Phungwayo, Richard Glover, Stacy Slechta, Troy Holdeman, Robyn Hartvickson, Amber Grant, Terry L. Poling, Terry D. Klein, Thomas Klein, Tracy Klein, William Smith, Richard Gibson, Jennifer Winbigler, Elizabeth Parker, Priyantha N. Wijewardane, Eric Bravo, Jeffrey Thessing, Michelle Maxwell, Amanda Horn, Catherine Healy, Christine Akamine, Laurence Chu, R. Michelle Chouteau, Michael J. Cotugno, George H. Bauer, Greg Hachigian, Masaru Oshita, Michael Cancilla, Kristen Kiersey, William Seger, Mohammed Antwi, Allison Green, Anthony Kim, Michaël Desjardins, Jennifer Johnson, Amy C Sherman, Stephen R. Walsh, Judith Borger, Nafisa Saleem, Joel Solis, Martha Medina, Westly Keating, Edgar García, Cynthia Bueno, Nathan Segall, Douglas Denham, Thomas Weiss, Ayoade Avworo, Parke Hedges, Cynthia Strout, Rica Santiago, Yvonne Davis, Patty Howenstine, Alison Bondell, Kristin J. Marks, Tina Wang, Timothy Wilkin, Mary Vogler, Carrie D. Johnston, Michele P. Andrasik, Jessica Andriesen ほか 1,063 名 - JAMA Network Open 2023 被引用: 23

  24. Invasive Pulmonary Aspergillosis Associated with High-Dose Inhaled Fluticasone

    著者: , , - New England Journal of Medicine 2000 被引用: 86